Stem Cell Clinic

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 269,250 shares of the company’s common stock, at a per share exercise price of $5.12, the closing trading price on September 8, and restricted stock units to acquire 2,125 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Read more:
Adamas Announces New Employment Inducement Grant

AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17, 2020 at 12:00 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://www.webcaster4.com/Webcast/Page/2495/37348

Read more:
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

imber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Virtual Presentation on Wednesday, September 16th at 12:30 PM ET Virtual Presentation on Wednesday, September 16th at 12:30 PM ET

Excerpt from:
imber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Virtual Presentation on Wednesday, September 16th at 12:30 PM ET Virtual Presentation on Wednesday, September 16th at 12:30 PM ET

See the rest here:
Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – 16, 2020.

Read more here:
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Resverlogix Provides Update Regarding Extension of its Filing Calendar

Confirms Annual Filings on SEDAR Confirms Annual Filings on SEDAR

More:
Resverlogix Provides Update Regarding Extension of its Filing Calendar

Axiom Presenting and Exhibiting at SCDM 2020 Virtual Conference September 13-16, 2020

Read more:
Axiom Presenting and Exhibiting at SCDM 2020 Virtual Conference September 13-16, 2020

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) --  NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.

See the original post here:
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th   

LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

Excerpt from:
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th   

Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society…

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.

Original post:
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society...